Understanding the Structure, Activity and Inhibition of Chorismate Synthase from Mycobacterium tuberculosis
Tuberculosis is considered a worldwide health problem mainly due to co-infection with HIV and proliferation of multi-drugresistant strains. The enzymes of the shikimate pathway are potential targets for the development of new therapies because they are essential for bacteria, but absent from mammals. The last step in this pathway is performed by chorismate synthase (CS), which catalyzes the conversion of 5-enolpyruvylshikimate-3-phosphate (EPSP) to chorismate. The aim of this article is to review the available information on chorismate synthase from Mycobacterium tuberculosis.
Keywords: Chorismate synthase; Genetic products; HIV; Mycobacterium tuberculosis; antimycobacterial agents; antiretroviral agents; bacteria; inhibition; polypeptide; shikimate pathway
Document Type: Research Article
Publication date: 01 March 2011
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content